Clinical ink announces GlucoseReady™

Fehlermeldung

Notice: Undefined property: stdClass::$ds_changed in eval() (Zeile 16 von /var/www/7/modules/php/php.module(80) : eval()'d code).
Notice: Undefined property: stdClass::$ss_search_api_url in eval() (Zeile 20 von /var/www/7/modules/php/php.module(80) : eval()'d code).
Notice: Undefined property: stdClass::$tm_title in eval() (Zeile 20 von /var/www/7/modules/php/php.module(80) : eval()'d code).

Winston Salem, NC, April 23, 2024 (GLOBE NEWSWIRE) -- Clinical ink , a global life science technology company, today announced the launch of GlucoseReady™ , a fully integrated GCP compliant digital platform designed for the new era of cardiometabolic clinical trials.

Metadata

Provider:

GlobeNewswire, Inc.

Retrieved on:

Dienstag, April 23, 2024

Information

Tags:

FDA, Blood, Diabetes, CGM, MD, Lung compliance, American Opportunity Tax Credit, Disease, Obesity, Patient, Actigraphy, GCP, BGM, Biomarker, Hypoglycemia, Medical device

Geotags:

HORSHAM, PA, US, NC

Zusammenfassung

Key Points:

Winston Salem, NC, April 23, 2024 (GLOBE NEWSWIRE) -- Clinical ink , a global life science technology company, today announced the launch of GlucoseReady™ , a fully integrated GCP compliant digital platform designed for the new era of cardiometabolic clinical trials.
The suite of tools includes disease specific electronic clinical outcomes (eCOA) assessments, behavioral assessment by the SPUR™ tool, lifestyle standardization, blood (BGM) and continuous glucose monitoring (CGM), digital weight scale and actigraphy.
Unique endpoint features include ability of BGM and CGM to trigger hypoglycemia eCOA within the platform in line with the latest FDA guidance.
Jonathan Goldman MD FACC FRCP, CEO of Clinical ink commented: “The next generation of Cardiometabolic trials require a new approach to understanding who the patients are and what they care about.

Winston Salem, NC, April 23, 2024 (GLOBE NEWSWIRE) -- Clinical ink, a global life science technology company, today announced the launch of GlucoseReady™, a fully integrated GCP compliant digital platform designed for the new era of cardiometabolic clinical trials. The suite of tools includes disease specific electronic clinical outcomes (eCOA) assessments, behavioral assessment by the SPUR™ tool, lifestyle standardization, blood (BGM) and continuous glucose monitoring (CGM), digital weight scale and actigraphy. Unique endpoint features include ability of BGM and CGM to trigger hypoglycemia eCOA within the platform in line with the latest FDA guidance. Novel compliance features include prediction, tracking and prevention of non-compliance and drop out at site and patient level. Partnerships with leading digital device developers further reinforce alignment with FDA expectation for regulatory compliance.

GlucoseReady™ provides modules which used separately or together support multiple therapeutic areas including diabetes, chronic weight management and obesity and NASH/MASH, within a single GCP platform designed for user friendliness, patient support as well as the requirements of an FDA inspection.

Jonathan Goldman MD FACC FRCP, CEO of Clinical ink commented: “The next generation of Cardiometabolic trials require a new approach to understanding who the patients are and what they care about. GlucoseReady™ is designed from the ground up to provide full real time transparency into patient behavior and lifestyle whilst capturing the full range of relevant symptoms, signs and biomarkers. We believe these user friendly tools can support the relationship between site and patient to improve the most important variable of all: retention. In addition, near real time data visualization provides sponsors with a new gold standard for data science.”

About Clinical ink

Clinical ink is a global life science company bringing data, technology, and patient-centric research together. Our deep therapeutic-area expertise, coupled with Direct Data Capture, eCOA, behavioral and dropout prediction, eConsent, telehealth, and digital biomarkers advancements (including use of Continuous Glucose Monitoring for detection of hypoglycemia), support the next generation of clinical trials and ultimately the clinical management of patients.

Alissa Dunkin
Clinical ink
[email protected]